CytoMed Therapeutics (GDTC) Receivables (2021 - 2025)

CytoMed Therapeutics (GDTC) has disclosed Receivables for 5 consecutive years, with $1.6 million as the latest value for Q4 2025.

  • Quarterly Receivables rose 306.51% to $1.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.6 million through Dec 2025, up 306.51% year-over-year, with the annual reading at $1.6 million for FY2025, 39.37% up from the prior year.
  • Receivables hit $1.6 million in Q4 2025 for CytoMed Therapeutics, up from $390008.1 in the prior quarter.
  • In the past five years, Receivables ranged from a high of $1.6 million in Q4 2025 to a low of $80187.7 in Q4 2022.
  • Historically, Receivables has averaged $729045.9 across 5 years, with a median of $581771.7 in 2021.
  • Biggest five-year swings in Receivables: plummeted 86.22% in 2022 and later surged 1156.86% in 2023.
  • Year by year, Receivables stood at $581771.7 in 2021, then plummeted by 86.22% to $80187.7 in 2022, then soared by 1156.86% to $1.0 million in 2023, then crashed by 61.3% to $390008.1 in 2024, then soared by 306.51% to $1.6 million in 2025.
  • Business Quant data shows Receivables for GDTC at $1.6 million in Q4 2025, $390008.1 in Q4 2024, and $1.0 million in Q4 2023.